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Background: Drug repurposing can accelerate the identification of effective compounds
for clinical use against SARS-CoV-2, with the advantage of pre-existing clinical safety data
and an established supply chain. RNA viruses such as SARS-CoV-2 manipulate cellular
pathways and induce reorganization of subcellular structures to support their life cycle.
These morphological changes can be quantified using bioimaging techniques.
Methods: In this work, we developed DEEMD: a computational pipeline using deep neu-
ral network models within a multiple instance learning (MIL) framework, to identify pu-
tative treatments effective against SARS-CoV-2 based on morphological analysis of the
publicly available RxRx19a dataset, This dataset consists of fluorescence microscopy im-
ages of SARS-CoV-2 non-infected cells and infected cells, with and without drug treatment.
DEEMD first extracts discriminative morphological features to generate cell morphological
profiles from the non-infected and infected cells. These morphological profiles are then used
in a statistical model to estimate the applied treatment efficacy on infected cells based on
similarities to non-infected cells.
Results: DEEMD is capable of localizing infected cells via weak supervision without any
expensive pixel-level annotations. DEEMD identifies known SARS-CoV-2 inhibitors, such
as Remdesivir and Aloxistatin, supporting the validity of our approach.
Conclusions: DEEMD is scalable to process and screen thousands of treatments in parallel
and can be applied to other emerging viruses and data sets to rapidly identify candidate
antiviral treatments in the future.
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The COVID-19 global pandemic has urged the research community to focus their resources
towards studying SARS-CoV-2 and discovering or identifying potential therapeutics. To
date, despite intense efforts, very few treatment options are available for those suffering
from COVID-19 [67]. Drug repurposing is an attempt to identify existing clinically approved
treatments with established pharmacological and safety profiles that could be rapidly redi-
rected towards clinical treatment of novel diseases such as COVID-19 [78, 109] (and refer-
ences within). The antiviral activity of candidate compounds can be tested using cell-based
systems of viral infection. The detection of the viral infection is achieved using molecular
tools such as antibodies directed at virus encoded proteins. In the case of newly emerging
viruses such as SARS-CoV-2, access to such molecular tools may represent an important
limiting step to rapidly developing cell-based assays to discover novel antiviral agents. Al-
ternatively, since human pathogenic viruses such as SARS-CoV-2 manipulate cellular path-
ways to reorganize the host cell morphology to support their life cycles [58, 18], developing
a computational method to perform quantitative analysis of virus-induced cell morphology
provides a unique approach to discover candidate antiviral molecules without the use of
viral biomarkers [8]. Virus infected cells can be treated with thousands of compounds at
different concentrations followed by staining of cellular structures with fluorescent dyes that
can be imaged using high-content screening fluorescence microscopes [74, 88]. Morphological
features can be extracted from images of infected and uninfected cells and then applied to
images of infected drug-treated cells to predict antiviral efficacy based on cellular morphol-
ogy. Thus, quantitative morphological analysis of cells as a computational method for drug
repurposing allows for accelerated parallel screening of multiple therapeutics [63].
It is worth mentioning that an early version of this work was accepted and presented at
Machine Learning in Computational Biology (MLCB) 20201. An extended version is under
review in IEEE Transactions on Medical Imaging.
1https://sites.google.com/cs.washington.edu/mlcb2020/
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The rest of this thesis is structured as follows: we first review the literature on drug
repurposing, high-throughput cell imaging and how it can be used to scale drug repurposing
studies, along with the computational multiple instance learning framework in Chapter 2.
Chapter 3 presents DEEMD and its components and discusses them in detail. We applied
DEEMD to a dataset of SARS-CoV-2 infected florescence microscopy images, as explained
in Chapter 4, and identified a list of 18 potential treatments effective for COVID-19. We
discuss our findings along with DEEMD’s limitations in Chapter 5. Finally, the this thesis
is concluded in Chapter 6.
2
Chapter 2
Background and Literature Review
2.1 Coronavirus
Named after its spike-like peplomers covering its surface, coronavirus has been known to
human since 1960s and were mostly associated with mild respiratory disease [64, 52, 45, 14,
12, 86, 91]. In the past 20 years, three major outbreaks have been related to this family
of viruses. During the first one which occurred in 2002–2003, over 8000 people from 26
countries were infected with severe acute respiratory syndrome coronavirus (SARS-CoV)
which had a reported 10% case fatality rate. The Middle East respiratory syndrome coron-
avirus (MERS-CoV) outbreak started around April 2012 in Middle East, Africa and South
Asia. Until November 2019, around 2500 labratory-confirmed cases of MERS-CoV have
been reported involving 27 countries. It is estimated that MERS-CoV has a mortality rate
of approximately 34% based only on the laboratory-confirmed cases. However, researches
believe this mortality rate is an overestimation, since mild cases of MERS-CoV would be
missed by the monitoring systems since little was known about it [3].
The most recent outbreak, presumably originating from Wuhan in China, started from
a Huanan wholesale seafood market in December 2019 and quickly became a global pan-
demic. To this date, more than 128 million positive Coronavirus cases have been reported
globally. Unfortunately, near 2.8 million people have lost their lives to it. Coronavirus dis-
ease (COVID-19), caused by SARS-CoV-2, has a variety of symptoms ranging from flu or
gastrointestinal irritation to acute respiratory distress syndrome, heart arrhythmias, stroke,
and death [34, 95, 1, 70, 99, 56, 6, 49]. Due to its high infection rate, diagnosis and therapy
for COVID-19 has been the major focus of researches for the past few months. Approval
of a novel therapeutic for COVID-19 can take several years, however, there has been major
progress on development and roll out of a vaccine. As of today, at least seven different
vaccines across three platforms have been rolled out in countries. At the same time, more
than 200 additional vaccine candidates are in development, of which more than 60 are in
clinical development [69, 54, 59, 21].
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2.2 Drug Repurposing and High-throughput Imaging
Drug repurposing is an active research area in the pharmaceutical industry in which exist-
ing drugs are used in alternative applications for which they were originally designed. Drug
repurposing has been shown to be an effective approach in many cases [78]. For instance,
Fingolimod was originally developed to prolong organ graft survival. But later through
drug repurposing, it was found to be effective against multiple sclerosis pathogenic im-
mune responses [9]. Drug repurposing studies develop and apply various approaches to test
their repurposing hypotheses. These approaches include computational methods, such as
genetic association or molecular docking, and experimental ones, e.g. phenotypic screening
or binding assays. However, deploying large-scale binding cell-based assays for large-scale
systematic analysis is expensive and slow to the point that it would not be practical. On the
other hand, high-throughput imaging assays can be used to screen numerous compounds
for morphological cell profiling and eventually their antiviral effectiveness with high effi-
ciency. Morphological cell profiling combined with recent advancements in computer vision
models can be leveraged to extract the morphological changes induced by each compound
in the sample population. These morphological features can lead to a better understanding
of the compounds interacting within the host cell, its molecular targets, and its pathways.
Image-based morphological analysis has been effectively utilized in small molecule profiling
[8, 97], identifying the mechanism of action [50, 20, 89], and drug repurposing [84, 63].
Recently, drug repurposing studies focused on COVID-19 to find FDA-approved clini-
cally understandable therapeutic compounds against SARS-CoV-2 [115, 51] (and references
within). Among multiple methodologies, high-throughput screenings have enabled image-
based morphological analysis of cells infected with SARS-CoV-2 [63, 38, 22, 75]. Mirabelli et
al. [63] used Huh-7 cell line samples infected with SARS-CoV-2 and applied a library of 1425
FDA-approved compounds at different concentrations for identifying compounds with an-
tiviral activity. The samples were later stained with anti-nucleocapsid protein, SARS-CoV-2
antibody, and dyes specific to cell organelles for imaging. They used CellProfiler software
[62] to extract morphological features from the infected cells, using anti-nucleocapsid protein
as indicator for regions of interest, and trained a random forest model to predict efficacy
scores for each treatment. These scores were used to select efficacious compounds for the
follow-up experimental triplicate dose-response confirmation. They identified 17 compounds
to possess effectiveness including Remdesivir, of which 10 are novel in vitro identifications.
Heiser et al. [38] used a morphological analysis pipeline one RxRx19a dataset, a fluores-
cence microscopy dataset of HRCE samples, to identify potential treatments for COVID-
19. The complete workflow is not outlined in their paper, since they are using proprietary
pipelines. They used a proprietary deep convolutional neural network to calculate dense em-
beddings for the sample images. These embeddings ar then used for calculating on-disease
projection and off-disease rejection scores per dose for each treatment. These scores were
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then aggregated and normalized using a proprietary algorithm to compute the hit-scores.
They reported that Remdesivir,GS-441524,Aloxistatin, Silmitasertib, andAlmitrine showed
moderate to strong effectiveness in their model, whereas, neither chloroquine nor hydrox-
ychloroquine demonstrated any significant effectiveness in their cultured cells. Similarly,
Cuccarese et al. [22] used an in vitro deep-learning-driven analysis of cellular morphology
on HUVEC cells with COVID-19-associated cytokine storm to identify potential candidates
for drug repurposing.
2.3 Multiple Instance Learning
Multiple instance learning (MIL), as a form of weakly supervised learning, has been under
the spotlight of research communities recently due to its ability to leverage weak supervision
for tasks that are conventionally considered heavily dependent on laborious human anno-
tations [11]. MIL was originally introduced for drug activity prediction [26] and recently it
has been applied in many different domains such as computer vision [94], medical imaging
and diagnosis [101, 10, 107], and in biology for applications such as mechanism of action
classification using microscopy images [50], identifying antigen binding peptides [108], pre-
dicting specific functional binding sites in microRNA targets [7] to name a few. Contrary
to conventional supervised learning methods in which every instance in the training data is
associated with a label, in MIL the learner is provided with a training set of labeled bags,
where each bag is a set of instances. The learner is tasked to predict a label for an unseen
bag given its instances. MIL algorithms can be categorized into three classes regarding how
and on what level they extract their required discriminative features [4]:
• Instance-space algorithms are based on the assumption that the information needed
for the bag classification lies within instances and are local. Hence, an instance-level
classifier is trained in the first place, and then an aggregation method is used to in-
tegrate the instance-level predictions into a single bag-level label. There are multiple
assumptions about the relation between the instance-level and bag-level labels [30].
The most commonly used assumption is the standard multiple instance assumption,
which has been incorporated in methods such as EM-DD [112], miSVM [5], MIBoost-
ing [104], and VF [57]. This assumption states that in a binary bag classification
configuration, each bag labeled as positive class contains at least one instance repre-
senting the positive class, whereas the negative class bags do not contain any instance
of positive class [60].
• In Bag-space algorithms, the learner extracts the discriminative information from
the whole bag as a composite entity of instances based on the assumption that the
discriminative features exist at the bag level, and predicts a label for the bag using
distance or similarity using classifiers such as K-NN or SVM in MInd and mi-Graph
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[15, 116]. Contrary to instance-space paradigm that uses local instance-level informa-
tion, this class of algorithms extracts global information by taking the whole bag into
account.
• In the Embedded-space class, the learner first maps all instances in the bag into
a vector in the embedding space, and then a classifier is trained on this embedding
space. Similar to the bag-space algorithms, the embedded-pace uses the global bag-
level information to learn the discriminative features for classification, however, the
difference between these two approaches resides in the feature extraction. While in the
bag-space methods the information is extracted implicitly via the distance or similarity
function, in the embedded-space algorithms this is done explicitly by the embedding
function that maps the bags into a vector space. This approach converts the multiple
instance classification problem into a conventional supervised classification one.
2.4 Deep Multiple Instance Learning
Considering the prevalence of deep neural networks and MIL ability to formulate and tackle
problems with weak supervision, the integration of both approaches was unsurprising. Deep
multiple instance learning uses a deep neural network model as a learner in the MIL frame-
work, and it has shown performance competitive with state-of-the-art in recent studies.
Hou et al., [40], reported an improved performance of a MIL based instance classifier with
extracted patches from whole slide tissue images for predicting the subtypes of glioma and
non-small-cell lung carcinoma cases. Campanella et al. [10] proposed an embedded-space
pipeline for classifying and finding potentially cancerous candidate regions on whole slide
tissue images by training an patch classifier coupled with a recurrent neural network to em-
bed and aggregate patch information for whole slide classification. They used an instance
classifier based on the standard MIL assumption to classify the extracted patches of the
whole slide tissue images, and then used the penultimate layer of the trained model as
an embedding for each instance. A recurrent neural network takes a bag in the form of
a sequence of its instances’ embeddings and aggregates them for the final bag-level label
prediction. Similarly, Ilse et al. [43] proposed a fully trainable deep MIL model combined
with an attention mechanism [103] to associate a learnable weight to each instance or its
embedding and evaluated it on two datasets of histology images for breast and colon cancer.
Applying the attention mechanism in the MIL context has been very limited in the literature
and due to the attention mechanism’s nature, it can only be applied to the embedded-space
methods [72]. In this context, the attention mechanism is integrated into the pooling func-
tion that aggregates the instances or their lower dimension embeddings into a fixed-size
tensor before predicting the bag label. In contrast, when using instance-space methods, at-
tention mechanism is not applicable since the instance aggregation is disjoint from instance
classifier training.
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Kraus et al. [50] introduced a new architecture for classification and segmentation of mi-
croscopy images using Noisy-AND pooling layer for aggregation of instances and showed im-
proved performance for mechanism of action classification on mammalian and yeast datasets.
Yan et al. [105] proposed a dynamic permutation-invariant pooling function for deep MIL
architectures that estimates each instance contribution to its bag label iteratively and re-
ported improved performance on 4 different classification tasks on various datasets. Recently,
Zhao et al. [114] proposed a embedded-space deep MIL based on a graph neural network for
predicting lymph node metastasis in colorectal cancer on histopathological images. Their
model consists of variational autoencoders and generative adversarial networks to extract
the discriminative features and embed the bags into a latent space. A graph convolutional
network is then applied on top of the extracted embeddings to predict the lymph node
metastasis.
2.5 Contribution
Virus-specific markers are not always included in high-throughput imaging studies that
investigate the effects of viral infection and drug treatments on a host cell morphology;
in these instances, the extent of viral infection is unknown. This scenario may also occur
during the very early stages of an outbreak or pandemic when limited virus specific tools
are available, such as when COVID-19 first emerged. When no pixel-level annotations are
available to specifically identify infected regions of the imaged cell population, MIL may
be used as an alternative strategy to localize viral infection and the corresponding effects
on host cell morphology. The imaged cell populations can be broken down into smaller
instances, single cells or patches, and the sample cell population label is utilized in the
MIL formulation. An instance-space approach would very well suit this problem for viral
infections such as SARS-CoV-2, that induce local morphological changes to cells. Based on
the standard assumption, we assume that if a sample cell population is infected, then there
should be at least one instance that contains infected cells. And a non-infected sample cell
population does not have any infected cells.
In this work, we present DEEMD: a computational pipeline that estimates treatment
efficacy using morphological features of cells extracted using a deep learning model. DEEMD
is scalable to process and screen multiple cell lines and thousands of treatments in parallel
and can accelerate the identification of clinically evaluated and FDA-approved compounds
with antiviral activity. We applied DEEMD on a public microscopy image dataset of SARS-
CoV-2 infected cells, and it identified treatment compounds that have been suggested in the
literature to be effective against COVID-19, further supporting the validity of the pipeline.
The specific design of the deep learning model allows us to localize infected cells via a
weakly supervised training procedure without expensive annotations. Localizing the infected
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cells allows us to better explain the model predictions, as well as enhances our biological
understanding of the morphological changes in cells induced by SARS-CoV-2.
To the best of our knowledge, this is the first work to approach the drug repurposing
problem via leveraging weak supervision through multiple instance learning. Many mor-
phological analysis pipelines utilize a viral-specific stain to localize infected regions of in-
terest in sample images for studying morphological changes induced by the viral. However,
these viral-specific stains are expensive and in case of an emerging virus, unavailable to
be utilized. Another approach taken by other morphological profiling pipelines, is to rely
on computer vision models to extract viral-related morphological features through massive
datasets without providing any annotations on infected regions of interest. DEEMD is an
attempt to integrate both these approaches through identifying infected regions in sample
images without requiring any viral-specific stains or annotations.
DEEMD could be used in the very early stages of an outbreak to quantify the effective-
ness of any known and approved compound and identify lead small molecules or compound
candidates that show therapeutic effectiveness against viral infection. The identified candi-
dates can then be used in more targeted testing once other molecular tools become available
and that the findings can be used in combination with other methods, such as fluorescent-




We first describe a high-level overview of the DEEMD before delving into the details.
DEEMD consists of two components: First component is a deep learning model which is
trained on microscopy images of untreated samples to extract discriminative morphological
features in MIL framework to distinguish between uninfected and SARS-CoV-2-infected
cell population images, further described in Section 3.1. Following infection of cells treated
with a drug, the trained deep learning model is used to extract a morphological profile for
each sample. These profiles are then aggregated and used in a statistical model, the second
component, to estimate the treatment efficacy per concentration, Section 3.4. Finally, all
dose-dependent efficacy scores are aggregated for each treatment to form the final identified
set of potentially effective treatments. In this context, we define treatment effectiveness as
how close a treated sample’s morphological profile is to uninfected cell profiles. We discuss
each component detail in the following sections.
3.1 Classification with deep MIL
In this work, we follow closely the training procedure described in [10, 105] for training an
instance classifier based on a relaxed version of the standard multiple instance assumption.
The training set D consists of n data points (X,Y) in form of (xi, yi) pairs where xi is
a fluorescence microscopy image along with its associated sample-level label yi with two
classes: active SARS-CoV-2 (cP ) and non-infected (cN ). Each sample image xi can be split
into N patches each referred to as xpji . We assume that each x
pj
i is associated with a patch-
level label ypji which is unknown and not included in the dataset D. Let M(θ) be a deep
neural network model responsible for predicting a patch-level label µpji for every patch x
pj
i
of each sample image xi. In the MIL terminology, modelM(θ) is an instance classifier since
it classifies each instance into active SARS-CoV-2 and non-infected classes. We define µpji to
be the modelM(θ) estimation of the unknown true patch-level label ypji given the dataset
9









where P[A] shows the probability of the event A.
Each training iteration starts with an exhaustive inference over all patches in the training
set and all corresponding µpji are estimated. Then for each sample image xi, all of its patch-
level estimated labels µpji , denoted as Mi, are sorted and the set of k patches with the




∣∣∣µpji = m(Mi, r)}, Kki , k⋃
r=1
tr, (3.2)
where we define m(S, r) to be the r-th greatest element in the set S.
The sample-level label yi is assigned to each set of patches in Kki , and the modelM(θ)




, between yi and µ
pj
i for
all patches in the set Kki . More specifically, we can break this process down into multiple
steps:
1. Given a patch pj and the label yi associated with its corresponding sample image xi,









i )− (1− yi)log(1− µ
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i ). (3.3)
2. We define the loss value for the sample image xi to be only inclusive of informative
patches, e.g. patches that we have confidence in their predicted infection probability.
In other words, we only include patches which are in the set Kki and take an overage



























∣∣∣yi = cP , i ∈ {1, · · · , n}}, YN = {yi∣∣∣yi = cN , i ∈ {1, · · · , n}}, (3.5)











where |A| represents the cardinality of A.
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. (3.7)
The reader is encouraged to refer to Section 5.6 for a detailed discussion on how hyper-
parameter k affects the training dynamics for a MIL learner.
3.2 Inference with deep MIL
Since the classification labels are only available for the sample images, aggregation of
the patch-level infection probabilities is required for performance evaluation and down-
stream analysis. For inference, each sample image is split into patches and a forward
pass through the model. This provides us with the estimated infection probabilities,
Mi =
{
P[ypji = cP |D;M(θ)]
}
pj∈xi









m(Mi, k) ≥ η
)
, (3.8)
where η is the cut-off threshold, selected based on the validation set and I(·) is an indicator
function.
For the MIL modelM(θ), hyper-parameter k is incorporated into the standard multiple
instance assumption so that the model can generalize to a more relaxed constraint: a posi-
tive (SARS-CoV-2 infected) sample image should contain at least k positive patches to be
considered positive and a sample image would be considered negative if less than k patches
are predicted to be infected. This generalized assumption is mathematically expressed in
Eq. 3.8:
3.3 MIL infection localization
Localization of the infected region is achieved using the estimated µpji . To form the infection
map Ai all patches need to be aggregated. Based on the set of all patches that overlap at
the pixel x(l,m)i , denoted as set Oxi(l,m), the value of infection map A
(l,m)
i is calculated by
the weighted average of its overlapping patches infection probabilities, {µpji }pj∈Oxi (l,m). We
opt to set sample weights based on the sample’s values, similar to the quadratic mean, but
using (µpji )α, where α < 1, instead of µ
pj











By using this averaging method, with α < 1 when all µpji ’s are smaller than 1, the average is
more sensitive to higher values, and smaller values have less diminishing power on the result
compared to simple averaging. This property is well-suited for infection localization since
patches with high infection probabilities do not get diminished by the adjacent overlapping
low probability ones. Finally, prior to rendering the infection map, a low-pass Gaussian
filter is applied to make the infection map smoother. For generating the infection map Ai
based on the MIL model,M(θ) we set α to 0.2.
3.4 Treatment Efficacy Estimation
DEEMD estimates the treatment efficacy based on its trained MIL model that compares the
morphological profile of drug-treated cells with those of untreated infected and uninfected
cells. We assume that an effective treatment would prevent drastic infection-induced mor-
phology changes in the cells, hence, the treated cells morphological profile would be similar
to that of uninfected ones. A statistical model takes in the infection probabilities predicted
by the MIL model and estimates the probability that a treatment is effective based on its
morphological similarities to uninfected cells.
For each sample image xi, the infection probability zi is calculated as:
zi = Median{µ
pj
i |pj ∈ K
k
i }. (3.9)
We define the set T cjti such that it consists of infection probabilities for every sample image
of a given treatment ti at concentration cj in the treated test set. We have to aggregate the
infection probabilities, zi, over the set T
cj
ti to minimize the inevitable variations that have
occurred during the sample preparation, treatment administration and image acquisition.
We define ecjti to be the dose-dependent estimated efficacy score of the treatment ti at con-
centration cj based on any model Ω(ω) capable of assigning an infection probability to a
sample image based its morphology. Since we do not have any assumptions on the distri-
bution of infection probabilities zi in the set T
cj
ti , we opt to use non-parametric statistics
related to the median of it, βcjti . We observed that the distribution infection probabilites
zi in the set T
cj
ti for any ti is heavily skewed and asymmetric, thus using Wilcoxon test is
misleading since it assumes a symmetric distribution for the data[98]. However, the sign test
is still valid[27]. Given a confidence level a, we can calculate the exact confidence interval for
the estimated median, denoted as CI(βcjti |a,Ω(ω)). To be more conservative about the false
positive rate, instead of using the point estimate βcjti , we use the least upper bound, supre-
mum, of CI(βcjti |a,Ω(ω)). The mathematical expression for the dose-dependent estimated
efficacy score of the treatment ti at concentration cj is:
e
cj
ti , T (T
cj










where T (·) is a descriptive statistic. The dose-dependent efficacy score ecjti reflects the model
Ω(ω) belief on the morphological similarity between the sample images in the set Tti,ci and
the uninfected ones in the training set. Close to 1 values for ecjti imply that the treatment
ti at concentration cj is effective against SARS-CoV-2. In this context, we assume that
the morphological profile of cells treated with an effective treatment is more similar to the
uninfected cells rather than infected ones.
To summarise all estimated dose-dependant efficacy scores of a given treatment ti for
raking all treatment compounds and identifying the effective ones, the estimated efficacy
















where ζ is a cut-off threshold and Cti refers to all available concentrations of treatment ti in
the treated test set. The treatment compounds that DEEMD identifies as effective against
SARS-CoV-2 are those for which at least one dose-dependent efficacy score is higher than





Here we describe the dataset that we used in this work along with the implementation and
design details needed for reproducing the presented results, and adapting DEEMD to other
domains and problems.
4.1 Dataset
We are using the publicly available RxRx19a dataset, which is the first morphological imag-
ing dataset of cells infected with SARS-CoV-2 [38]. The dataset consists of human renal
cortical epithelial (HRCE) and African green monkey kidney epithelial (VERO) cell lines
subjected to three different conditions: 1) mock uninfected control, 2) infection with ultra-
violet (UV)-light inactivated SARS-CoV-2 (irradiated for 20 minutes), or 3) infection with
SARS-CoV-2 at multiplicity of infection of 0.4, as illustrated in Fig 4.1. All samples were in-
cubated for 96 hours. A library of 1672 small molecules and FDA-approved treatments were
applied to a subset of active SARS-CoV-2 infected samples in 6+ half log concentrations
with six replicates per dose for each compound.
All cells were stained with five fluorescent dyes detecting various subcellular structures,
each imaged in a separate channel on a fluorescent confocal high-content imaging micro-
scope. The dyes include Hoechst (nucleus), Syto14 (nucleoli and cytoplasmic RNA), phal-
loidin (actin cytoskeleton), Concanavalin A (ConA; endoplasmic reticulum) and Wheat
Germ Agglutinin (WGA; Golgi and plasma membrane). In Table 4.1, a representative set
of sample images from each condition. The dataset consists of more than 300K 5-channel
labeled images of size 1024× 1024 and is publicly available through the Recursion website:
www.rxrx.ai/rxrx19a.
For this work, we only used the HRCE cell line and merged the mock control and the
UV inactivated control into a single uninfected class, as no cytopathic effects were observed
in either condition [38]. We also verified this by using each sample image’s corresponding
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deep learning embeddings included in the dataset. We decided to merge mock control and
UV inactivated into a single class as they were indistinguishable by a trained classifier (data
not shown).
4.2 Cell nucleus count in the sample images
Figure 4.2: Distribution of the nuclei count
in the stitched well sample images. The
non-infected class consists of samples from
both Mock and UV Inactivated SARS-CoV-
2 classes.
RxRx19a dataset includes Hoechst stain
which targets nucleus. We used this stain
to identify and count the cells in each sam-
ple image for both explanatory analysis and
preprocessing the data. We first stitch im-
ages of 4 adjacent sites of each well on
each plate to reconstruct the image of whole
sample cell population in each well. This
step is necessary to avoid nuclei multiple
counting. We localize and count the nuclei
in each sample image using a segmenting
pipeline based on Otsu thresholding. We
used this pipeline to exclude any sample im-
ages which did not contain any detectable
cells from the dataset. The distribuion of the nuclei count in the sample images for infected
and non-infected samples are shown in Fig 4.2. The cell nucleus count is significantly lower
in the infected samples (using two-sided Mann-Whitney test with p = 0.0).
4.3 Baseline Classification Models
To compare the MIL modelM(θ) performance, two other deep learning model are trained:
A model that is trained with the conventional training procedure for training convolutional
neural networks by minimizing a cross-entropy-based loss function, similar to Eq. 3.4, with
full resolution sample images as input. Denoted as W(φ), this model will be referred to as
whole-image based model W(φ) throughout this thesis. Unlike most deep neural network
classifiers, the input sample image is not down-sampled, and the full resolution version was
used to make the comparison fair. The whole-image based model W(φ) takes in the sample
image xi and calculates infection probability for that sample population.
Instead of limiting the model to only use k instances with the highest probabilities within
each bag for training, we can have a reasonable alternative approach of using all instances in
the bag and assigning them with the bag-level label. There are studies in histopathology such
as [19] that used this alternative approach and their proposed model outperformed other
models at their respective tasks. We refer to this model as the patch-based model V(ψ) in
the text. Similar to MIL instance classifier, V(ψ) calculates a patch infection probability
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for all patches in the input sample image xi. Intuitively, in this approach the model would
potentially be able to eliminate the effect of noisy labels and estimate the true distribution
of the instance labels given large enough training data. This approach is an extreme case
of the MIL training procedure in which k = N is where N is the total number of instances
within a bag.











Where η is the cut-off threshold, selected based on the validation set, and I(·) is an indicator
function.
4.4 Implementation Details
We used a 5 cross-fold validation approach for training and testing each model. The HRCE
sample images in RxRx19a dataset are split into 4 non-overlapping sets: 1) training, 2)
validation, 3) untreated, and 4) treated test sets consisting of 20K, 5K, 6K, and 247K
sample images respectively. The training set is used for updating the weights and training
the neural networks using backpropagation, whereas the validation set is used to tune hyper-
parameters. The performance of the tuned model is measured on the held-out untreated test
set, while the treated test set is solely used for estimating the efficacy of the treatments. All
sets are balanced in terms of class labels except for the treated test set which only consists
of active SARS-CoV-2 infected sample images.
All models are based on ResNet34 architecture, pretrained on ImageNet with a modified
input layer to accommodate 5-channel inputs [37, 25]. Each model was trained for 150
epochs, monitored for early stopping, with Adam optimizer at a learning rate η = 10−4,
β1 = 0.9 and β2 = 0.999, [47], with a batch size of 128. All hyper-parameters were tuned
with respect to the model’s performance on the validation set. Sample images are channel
normalized using the empirical means and standard deviations calculated on the training
set. We used η = 0.5 for evaluating the performance of the models. For the treatment
efficacy estimation, ζ was set to 0.5 and a confidence level of 0.95% was used in the sign
test. We used PyTorch framework [73] for model training and evaluation and treatment
efficacy estimation was coded using R [79].
For both the MIL model M(θ) and the patch-based model V(ψ), we used a uniform
grid of 256×256 patches with 50% overlap, resulting in 49 patches per sample image. Since
we wanted DEEMD to be applicable to other microscopy imaging datasets with minor
modifications, we choose a uniform grid of patches over a cell-based segmentation map.
Although a cell-based segmentation map could potentially provide a single cell resolution
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infection map, it is heavily dependent on the stains used in the imaging procedure, which
in turn reduces the pipeline generalization. Based on the validation set, we set the hyper-
parameter k for the MIL modelM(θ) to 2. The whole-image based modelW(φ) was trained
on full-resolution (1024× 1024) sample images without any input downsampling.
We trained the models on a single Nvidia TITAN V GPU. Notice that the effective
training set for the MIL modelM(θ) on each training iteration is k/N of the whole training
samples, thus its training is N/k times faster compared to the patch-based model V(ψ). The
patch-based model V(ψ) even has longer training time than the whole-image based model
W(φ) since the patches are overlapping. Thus, the MIL model M(θ) is computationally
more efficient compared to the other two.






















Figure 4.3: Cell infection probability as a func-
tion of MOI in a simple modeling.
Choosing an optimal value for hyper-
parameter k is crucial to the performance
of MIL models since it effectively controls
the amount of noise in the training labels.
The hyper-parameter k is the number of top
high probability instances in each bag used
for loss calculation in each training itera-
tion, 3.4. Tuning this hyper-parameter can
be either based on problem-specific domain
knowledge or a performance metric on the
validation set. For the problem of estimat-
ing the treatment efficacy against SARS-
CoV-2, the choice of optimal k was found
based on incorporation of domain knowl-
edge and common model performance met-
rics.
In a simple yet reasonable modeling,
let’s assume that the virions enter the cells
independent of each other and X is a random variable that counts the number of virions
entering a cell. Since we are dealing with a counting process, it is reasonable to assume that
random variable X comes from a Poisson distribution with parameter m, which is actually
the multiplicity of infection or MOI X ∼ Poi(m). The probability of a cell being infected is
calculated as follows:
P[A cell is infected] = 1− P[X = 0] = 1− e−m (4.2)
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The probability of a cell being infected is shown in Fig 4.3 as a function of MOI. Based
on the data provided in [38], in the preperation process of the the RxRx19a dataset, the
samples were infected with a MOI of 0.4. Based on our modeling of the infection process, this
value would indicate that around 33% of the cells in each sample are infected on average.
Figure 4.4: Precision-Recall curve for candi-
date optimal values of k
We incorporate this domain knowledge
about the expected number of infected cells
within each sample image in selecting the
optimal value for hyper parameter k. Since
we are using a uniform grid of overlapping
patches for the sample images, the number
of the selected patches in the set Kki can not
be directly translated into the fraction of
the infected cells within each sample image.
The area of the infected regions based on
the infection maps can be a good approx-
imation for the faction of the infected im-
aged cells. We trained multiple MIL mod-
els with different values for the hyper-
paremeter k ∈ {1, 2, 3, 5, 10, 15, 25, 49}.
Next, we calculated the fraction of pixels
that were higher than the cutoff threshold
η in the generated infection map for each sample images in the validation set for all of the
MIL models, as shown in Fig 4.5. We can see that when k equals to 1 or 2 or 3, the average
of the distribution is close to the theoretical calculated value using the MOI. Hence, these
3 options are candidates for the optimal value for k. Finally, to select the optimal value
between these 3 candidates, we turn to the average precision metric. As shown in Fig 4.4,
we can see that the models have a very close AUC, but when K is 2 the performance is
slightly better and thus we set k to be 2.
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Figure 4.1: RxRx19a dataset includes monolayers of normal HRCE cells in three viral con-
ditions: Mock, UV Inactivated SARS-CoV-2, Active SARS-CoV-2. After incubation for 96
hours, the samples were fixed and stained with 5 dyes and imaged on a fluorescent confocal
microscope.
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Table 4.1: Representative sample images from each condition in the RxRx19a dataset: Mock,
UV Inactivated SARS-CoV-2, Active SARS-CoV-2, and Treated Active SARS-CoV-2. Cells
were fixed and stained with fluorescent dyes each detecting a specific subcellular structures
and imaged on a fluorescent confocal high-contentimaging microscope. For better visualiza-
tion, each dye image is color-inverted. The composite image is constructed by overlaying
each stain in a color channel: Hoechst (violet), Syto14 (red), Phalloidin (green), ConA
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Figure 4.5: The distributions of the fraction of infected pixels in each sample image in the




5.1 The MIL model can accurately predict SARS-CoV-2 in-
fection
Figure 5.1: Comparison of precision-recall
curves. All three models are capable of ac-
curately classifying the sample images in the
untreated test set. A random classifier is in-
cluded as a reference.
We evaluate the performance of the MIL
modelM(θ), along with two baseline mod-
els, on the untreated test set in terms of
the area under the curve for precision-recall
curve, or average precision, as shown in
Fig 5.1. The precision-recall curve effec-
tively represents the trade-off between pre-
cision and recall for all possible cut-off val-
ues based on the model predictions. All
three models are capable of accurately clas-
sifying the sample images into non-infected
and SARS-CoV-2 infected classes, with an
average precision of ≈ 0.99. The perfor-
mance of the models is independent of the
learner architecture; similar results were ob-
served with models based on VGG16 archi-
tecture [85].
High average precision implies that
these models have learned morphological
features that can be generalized to the un-
treated test set for accurate classification,
however, the learned feature spaces have
drastically different characteristics due to their input and training procedures. The MIL
model M(θ) has learned to extract highly discriminative features from micro-populations
or single cells whereas the whole-image based modelW(φ) focuses on the macro-population
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of cells and learns morphological features of the population, which are not as detailed as
the MIL model M(θ)’s. The patch-based model V(ψ) lies in between those two models in
the spectrum; on the one hand it has been trained using patches with micro-population
features, but on the other hand, the labels it was provided for training were noisy. Thus,
this model is not focused on the details as the MIL modelM(θ). These shifts in the learned
feature spaces are further transferred to the downstream analysis of treatment efficacy, as
discussed in Section 5.3 and Section 5.5 .
5.2 Visualization of the MIL modelM(θ) morphological fea-
ture space
To better understand the MIL modelM(θ) learned morphological feature space, we visual-
ized the penultimate layer in its ResNet34 architecture. We trained UMAP dimensionality
reduction [61] on the training set and use it to project the patched sample images from
the untreated test set to get the 2-dimension projections. The calculated projections are
demonstrated in Fig 5.2. The original patches are also overlaid on top of the points to fur-
ther demonstrate the morphological differences between the two classes and the transition
between the two. We can see that there is a rather smooth transition from the nonin-
fected samples to the infected ones. The RxRx19a dataset does not include a fluorescent
marker specific for SARS-CoV-2 that can verify which individual cells in a sample image
are infected, thus the extent of infection is not known and cannot be verified. However,
the fraction of patches predicted as being infected by the MIL model M(θ) is consistent
with a SARS-CoV-2 MOI of less than one used in the preparation of the RxRx19a dataset.
We further explain the morphological features that we hypothesize the MIL modelM(θ) is
sensitive to in Section 5.8.
5.3 DEEMD dose-dependent efficacy scores are well-structured
We assume that an efficacious treatment is able to effectively stop viral infection and prevent
major infection-induced morphological changes in the cell population. Using morphological
analysis we can estimate treatment efficacy by profiling the treated and infected cell mor-
phology and quantifying its similarity to non-infected and infected morphology. We applied
DEEMD to the infected and treated cell images from the RxRx19a dataset which resulted
in a ranked list of potential efficacious treatments against SARS-CoV-2, EM(θ) shown in
Fig 5.3.
The dose-dependent efficacy scores for top ranked effective compounds identified by
DEEMD are shown in Fig 5.4-(a). As is expected for effective antiviral compounds, the dose-
dependent efficacy score of the identified treatments increases with increasing concentration,
similar to the fitted logistic curve. We expect to observe higher effectiveness with increasing
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Figure 5.2: Visualization of the MIL modelM(θ) learned morphological space. Each data
point is a patch from the sample images in the untreated test set. Some of the original
patches are overlaid for better visualization of the transition. The projected points are color
coded: purple indicates low probability of being active SARS-CoV-2 and, by transition-
ing into yellow, the infection probability increases.The composite image is constructed by
overlaying 3 stains: Hoechst (blue), Phalloidin (red), and ConA (green).
concentration of a treatment with antiviral potency against a specific target, up to the point
that it does not cause toxicity, interfere with vital cellular functions, or drastically alter cell
morphology. Importantly, most of the identified compounds were previously demonstrated to
have antiviral activity against SARS-CoV-2, by other drug repurposing studies for COVID-
19 based on morphological profiling [63, 38, 22], supporting DEEMD’s methodology. On
the other hand, if we compare the same plots for the predictions based on the whole-image
based modelW(φ) to those of the DEEMD, we notice that the estimated efficacy scores are
scattered randomly among all treatments and lack any form of structure or pattern, Fig 5.4-
(c). As mentioned in Section 5.1, the patch-based model V(ψ) is a hybrid of the other two
models in terms of its training. This hybridization also manifests itself in Fig 5.4-(b). We
can see that the estimations are slightly structured, not as much as DEEMD’s. Implying
that the model was not able to extract the informative features and information completely






































0.22 0.33 0.44 0.56 0.67 0.78 0.89 1.00
Fraction of MIL models
Figure 5.3: Ranked list of DEEMD identified treatments EM(θ) with their DEEMD efficacy
scores eti on the y-axis. The bars are color-coded based on the fraction of the MIL models
that identify it as effective.
5.4 DEEMD identified treatments are reoccurring in the lit-
erature
DEEMD has identified treatments that are reported in the literature to possess therapeutic
activity against SARS-CoV-2 [63, 38, 22, 109]. In Fig 5.5 we compare DEEMD efficacy scores
to hit-scores reported by Heiser et al. [38], which similarly used the RxRx19a dataset. We can
see that reoccurring treatments with high DEEMD efficacy scores, namely Remdesivir, GS-
441524, and Aloxistatin were also assigned a high hit-score by Heiser et al. (ρ = 0.56, p =
0.02). In the following, we review DEEMD top ranked identified treatments and briefly
discuss their potential mechanisms of action against SARS-CoV-2 infection. In Table 5.1, a
complete list of studies for all of the identified treatments are presented. We also compare
the DEEMD dose-dependent efficacy score for these compounds to previously reported IC50
values as a measure of validity whenever such data is available; however we acknowledge
that IC50 values from in vitro studies might not be exactly transferable to clinically relevant
concentrations. It should also be noted that due to differences in experimental design, such
as cell line timing of treatment and duration of infection, IC50 values from in vitro studies
can vary widely.
• The most well-known treatment in EM(θ) is Remdesivir and its metabolite,GS-441524.
Previously studied for their antiviral effectiveness against Ebola virus, these com-
pounds target the virus-encoded RNA-dependent RNA polymerase complex needed
by RNA viruses to replicate their genome [33]. Multiple studies and clinical trials
have found that both compounds are effective against SARS-CoV-2, which led to its
emergency approval by the FDA [109, 38, 22, 63] (and refrences within). DEEMD
dose-dependent efficacy scores for Remdesivir are shown in Fig 5.4-(a). We can see
that the DEEMD efficacy score is persistently close to 1 for concentrations in 0.3−10
µM which is consistent with IC50 values reported by other in vitro studies [93].
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Remdesivir Digoxin Aloxistatin Colchicine Mitoxantrone

























(a) DEEMD dose-dependent efficacy scores based on MIL modelM(θ) with k = 2
Remdesivir Digoxin Aloxistatin Colchicine Mitoxantrone





















(b) Dose-dependent efficacy scores based on the patch-based model V(ψ)
Remdesivir Digoxin Aloxistatin Colchicine Mitoxantrone





















(c) Dose-dependent efficacy scores based on the whole-image based model W(φ)
Figure 5.4: Estimated efficacy scores for top ranked identified treatments in EM(θ). (a) Es-
timated Dose-dependent efficacy scores for DEEMD top-ranked treatments with k = 2. The
x and y axes show Log10(Concentration) and dose-dependent efficacy score for each com-
pound. The violins show the estimated distribution of estimated scores for each concentra-
tion, along with the data points. A violin is opaque if DEEMD identified that concentration
to be effective, i.e. ecjti ≥ ζ. We used all of the data points, Tti , to fit a logistic regression
to better visualize the trend. (c) and (b) are similar plots for predictions based on the
whole-image based model W(φ) and the patch-based model V(ψ) respectively.
• Digoxin is a treatment used for heart disease with a well-established safety profile.
Multiple in vitro drug repurposing studies for COVID-19 reported its ability to inhibit
SARS-CoV-2 replication [93]. The exact mechanism of action for viral inhibition is
not identified yet, however, Cho et al. [16] hypothesised that Digoxin inhibition occurs
at the step of viral RNA synthesis. They used multiple FDA-approved treatments, in-
cluding Digoxin, on SARS-CoV-2 infected Vero cells. To understand how the drugs


























−0.5 −0.4 −0.3 −0.2 −0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0












Clinical Trial No Yes
0.22 0.33 0.44 0.56 0.67 0.78 0.89 1.00
Fraction of MIL models
Figure 5.5: Comparison of DEEMD efficacy scores and Heiser et al. hit-scores [38] for treat-
ments in EM(θ). Each data point is color-coded based on the fraction of the MIL models that
identify it as effective and its shape indicates whether the treatment has gone into clinical
trial against COVID-19. The y-axis represents the DEEMD efficacy scores and hit-scores
are on the x-axis.
1) prior to infection (prophylactic), 2) at the time of infection (entry), and 3) after
the infection (therapeutic). They reported that Digoxin showed high efficacy follow-
ing prophylactic and therapeutic administration but failed to effectively reduce viral
replication when administered at the time of infection. However, it should be noted
that Digoxin exhibited cytotoxicity, as reported by Mirabelli et al [63]. Fig 5.4-(a)
shows the DEEMD estimated dose-dependent efficacy scores for Digoxin; it passed
the threshold on 0.3 µM which is aligned with multiple studies that found an in vitro
IC50 of 0.2 µM. We hypothesize that the DEEMD dose-dependent efficacy scores are
not conclusive for higher concentrations because of Digoxin reported cytotoxicity.
• Through multiple clinical trials, low doses of Colchicine were found to reduce the
risk of cardiovascular events in both patients with cardiovascular disease and those
patients who had experienced a myocardial infarction [66]. Colchicine is an orally
administered anti-inflammatory drug, which inhibits polymerization of tubulin and
microtubule assembly, and affects a range of cellular immunity pathways [109]. The
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clinically demonstrated effects on inflammation and associated illnesses have posi-
tioned Colchicine as a candidate drug to treat COVID-19. While previous works have
presented conflicting conclusions regarding the efficacy of Colchicine [24], multiple
clinical trials have found it to be effective against SARS-CoV-2 [92]. As shown in
Fig 5.4-(a), DEEMD predicted it to be effective at concentrations of 0.3− 3 µM.
• Aloxistatin (E-64d) is another potential candidate treatment reported in the literature
as an effective agent against SARS-CoV-2. Aloxistatin is a membrane-permeable ir-
reversible cysteine-protease inhibitor of calpains and cathepsins. Recent studies have
shown that SARS-CoV-2 requires cathepsin L to enter some cell types. Aloxistatin
can significantly reduce entry of SARS-CoV-2 pseudovirions by inhibiting cathepsin
L. [71, 109, 82] (and references within). Fig 5.4-(a) shows DEEMD estimated dose-
dependent efficacy scores for Aloxistatin. As we can see, the estimated efficacy is higher
than cutoff threshold ζ at 0.3 and 10 µM. Olaleye et al. used Vero cells to investi-
gate the antiviral activity of several compounds including Aloxistatin for which they
reported an in vitro IC50 of 22 µM [68]. Two additional studies [38] and [22] using
morphology-based approaches found that Aloxistatin shows strong efficacy without
inducing morphological changes to cells.
• DEEMD also identified Mitoxantrone to be effective against SARS-CoV-2, as shown
in Fig 5.4-(a). Fig 5.8 suggests that there is a consensus between other MIL models on
its effectiveness. The cell surface heparan sulfate (HS) is a molecule commonly found
on the membrane and on extracellular proteins of cells that assists the endocytosis of
many cargos, including SARS-CoV-2 spike. Recently, Zhang et al. reported that HS
facilitates spike-dependent viral entry of SARS-CoV-2 [111]. They experimented with
inhibitor drugs that target the HS-dependent cell entry pathway, and observed that
Mitoxantrone inhibited viral entry by directly binding to cell surface HS.
• DEEMD also identified three compounds, Mebendazole, Oxibendazole and Albendazole
which belong to a large chemical family of Benzimidazoles that are used to treat
nematode and trematode infections, Fig 5.4-(a) and Fig 5.8. These three compounds
specifically have not yet been demonstrated to exhibit activity against SARS-CoV-2
or COVID-19. However, some antiviral activity against other viruses have been found
using Benzimidazole derivatives [36] and thus based on our analysis, these should
be further examined for activity and possible mechanism of action against SARS-
CoV-2. It is worth mentioning that these compounds have been suggested in some
computational drug repurposing studies to have effectiveness against SARS-CoV-2,
but the efficacy of them in animal or human models is yet to be tested [96, 29, 53].
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Rank Compound Studies
1 Remdesivir [109, 38, 22, 63, 93, 55, 77, 100, 106, 110, 17]
2 Digoxin [93, 16]
3 Aloxistatin [71, 109, 82, 68, 38, 22]
4 Colchicine [109, 24, 92, 35, 81]
5 Mitoxantrone [111]
6 Mebendazole [96, 29, 53]
7 Oxibendazole [53]
8 GS-441524 [83, 55, 77, 100, 106, 110]
9 Thymoquinone [2, 28, 87, 102]
10 Lasalocid [90]
11 Digitoxin [44, 48, 76]
12 Venetoclax [31]




17 Gemcitabine [106, 113, 41]
18 Podophyllotoxin [39]
Table 5.1: Ranked list of DEEMD identified treatments, EM(θ), along with drug repurposing
or clinical studies that reported to show effectiveness against SARS-CoV-2 or COVID-19.
5.5 DEEMD identified treatments are sensitive to selection
of k
Choosing an optimal value for hyper-parameter k is crucial to the performance of MIL
models since it effectively controls the amount of noise in the training labels. The hyper-
parameter k is the number of top high probability instances in each bag used for loss
calculation in each training iteration, 3.4. Tuning this hyper-parameter can be either based
on problem-specific domain knowledge or a performance metric on the validation set. For
the problem of estimating the treatment efficacy against SARS-CoV-2, the choice of optimal
k could be based on the MOI for the infectious agent. However, due to the limited under-
standing of SARS-CoV-2 and insufficient experimental details about the data generation
procedure, we turned to using a performance metric. Using our main objective of identi-
fying effective treatments for tuning hyper-parameters is not feasible because no ground
truth data about effective treatments against SARS-CoV-2 exists. Instead, we quantify
the hyper-parameter search space by each model’s performance on classification of SARS-
CoV-2 infected versus non-infected sample images in the validation set. We measured and
compared the average precision for MIL models with k ∈ {1, 2, 3, 5, 10, 15, 16, 25, 49} and
the MIL model with k = 2 showed the best performance. When we compared the dose-
dependent efficacy scores for the treatments in EM(θ), with k = 2, across different values for
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k, Fig 5.8, we observed that in most cases, the fitted logistic regression retained its shape
and the inflection points are close together; suggesting a consensus, almost independent of
choice of k, between the MIL models on the degree of effectiveness for various treatments.
When comparing DEEMD configurations with different values for k, multiple reoccur-
ring treatments were observed. As shown in Fig 5.5, most of the treatments in EM(θ) have a
high recurrence rate in the MIL models, implying their distinguishable ability to suppress
viral-induced morphological changes. We noticed that based on the patch-based model V(ψ)
only three treatments were identified to be effective: Remdesivir, GS-441524, and Aloxis-
tatin, which are among the most commonly identified treatments both in COVID-19 drug
repurposing studies and multiple MIL models with different k, as shown in Fig 5.5. This
observation suggests that for high values of k the amount of noisy labels drastically changes
the dynamics of the training. The learned feature space lacks the required sensitivity for
downstream analysis of treatment identification, while the model is still capable of accu-
rately classifying the sample images into infected and non-infected classes.
5.6 Using MIL results in less noisy labels in the training
compared to the patch-based models
As mentioned in subsection 4.3, the patch-based model V(ψ) trains the model in the presence
of noisy labels. To better understand this model and compare it to the MIL modelM(θ),
it would be insightful to measure how much noise is in the training labels for both models.
Each image is split into N patches and there are Np positive samples and Nn negative
samples in the dataset. We define the label noise in the dataset to be the ratio of the
samples correctly labeled in the dataset to the total number of samples. Without loss of
generality, assume that the fraction of the patches in a sample image that are truly infected
has an expected value of λ. Therefore, the expected noise ratio (NR) for the MIL model
M(θ) and the patch-based model V(ψ) can be expressed as follows:
NRM(θ) =






By defining r(λ, kN ) to be the log ratio of NRV(ψ) to NRM(θ), we can quantitatively









| kN − λ|
)
. (5.2)
When r(λ, kN ) ≥ 0 the MIL model M(θ) has less noisy labels compared to the patch-
based model V(ψ). The landscape of r(λ, kN ) is visualized in Fig 5.6 for closer inspection.
To ensure the numerical stability of r(λ, kN ) and keep it bounded on the y = x line, a small
value ε was added to NRM(θ).
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Figure 5.6: Contour plot for r(λ, kN ), all pos-
sible values for λ and kN are shown on the x
and y axis respectively.
One can notice that in almost three
forth of the cases, r(λ, kN ) ≥ 0, meaning
that the MIL model M(θ) has less noisy
labels in its training procedure on average,
hence, the model converges faster to an opti-
mum point. Moreover, the MIL modelM(θ)
training procedure results in a more effi-
cient training both in terms of computation
footprint and extracted features. The model
is using only kN of the training set for up-
dating the weights. This is Nk times faster
than using the whole dataset in the patch-
based model V(ψ). And more importantly,
the patches that are selected for training
the MIL model M(θ), would contain more
discriminative features since they were top-
ranked among all patches in their samples
for their informativeness. Finally, the MIL modelM(θ) has the capability of incorporating
domain knowledge about the problem into the training by the choice of hyper-parameter k.
By choosing k based on prior or domain knowledge, the MIL model M(θ) can iteratively
refine its training dataset towards for less noisy labels.
5.7 The MIL model identifies predictive patches
Localization of infected regions in a sample image can be done by aggregating all estimated
patch-level labels µpji to generate an infection map (refer to Section 3.3 for details on the
aggregation procedure). These maps can be used to better understand and explain the MIL
model M(θ) classification predictions as well as providing an annotation for patches that
contain SARS-CoV-2 infected cells. Notice that in the calculation of these maps, no form
of annotation was used; instead, the MIL model uses sample-level labels to localize the
infection. Fig 5.7 shows some representative examples from the untreated test set, overlaid
with infection maps predicted by the MIL model M(θ). Visual inspection of the infection
maps and regions that are predicted with high infection probability, annotated as bright
white, suggests that the MIL modelM(θ) is focused on high intensity stained areas, which
we predict to reflect cell death or cytopathic effect, detectable in all channels, except for
Hoechst.
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Figure 5.7: Infection map for a diverse set of examples. Representative examples from the
untreated test set overlaid with their corresponding infection maps. The intensity of the
white color shows the probability of infection. The composite image is constructed by over-
laying each stain in a color channel: Hoechst (violet), Syto14 (red), Phalloidin (green), ConA
(blue), and WGA (cyan).
5.8 MIL infection maps and cytopathic effects
We further inspected the infection maps generated by the MIL modelM(θ), Fig 5.7, on the
infected sample images from the test set to investigate if we can understand or interpret the
patches and features that are triggering the model to identify them as infected. The high
infection probability patches are mostly concentrated around high intensity stained features,
detectable in all channels, except for Hoechst. These are presumed to be dead or damaged
cells or other cytopathic effects (CPE) resulting from SARS-CoV-2 infection. CPE refers
to changes in host cell structure as a result of viral infection and SARS-CoV-2 is known to
be a cytopathogenic agent [117] for example SARS-CoV-2 is known to cause cell death and
to induce syncytia formation (fusion of adjacent cell membranes). CPE can be measured
indirectly by using luminescent cell viability assays [80], however, the RxRx19a dataset
does not include a specific viability marker, hence CPE can not be quantified on these
samples. Nonetheless, some forms of putative CPE are detectable in the highlighted regions
in the infection maps. We hypothesize that the brightly stained areas are cells or subcellular
structures that are taking up the cell dyes non-specifically due to changes associated with
cell death such as loss of membrane integrity, cell shrinkage, and nuclear fragmentation etc.
[23]. In support of this, we also observed that the cell nucleus count is significantly lower
in the infected samples which is also suggestive of cell death. This suggests that the MIL
modelM(θ) has incorporated biologically relevant morphological features into the infection
map, as is expected.
5.9 DEEMD is limited by drug toxicity
Drug toxicity refers to a compound’s negative side effects on a living cell, as the compound
can disrupt crucial cellular functions and pathways to the extent of causing cell death.
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Hoechst Syto14 Phalloidin ConA WGA
Table 5.2: More examples of the infection maps seperated for each stains. For better visu-
alization, each dye image is color-inverted.
Taking drug toxicity into consideration is essential for optimizing the concentration of the
compound needed for optimal efficacy [65]. It is noteworthy to clarify that a low efficacy
score ecjti estimated by DEEMD does not necessarily indicate dose or treatment ineffective-
ness against SARS-CoV-2. If the treatment has toxic effects or induces other changes in
cell morphology, the sample morphology may no longer resemble either the uninfected or
SARS-CoV-2 infected class; subsequently, the model’s prediction would not be conclusive.
Currently, DEEMD only relies on the assumption that if the drug is toxic, the treated cell
morphology would not be similar to uninfected cells, thus the model estimates a low effi-
cacy for a toxic compound. A more complex model capable of integrating drug toxicity with
cell morphology is required to properly capture the dynamics of the treatment compound,
toxicity and effects on cellular morphology, including cell death.
The RxRx19a public dataset does not include images from healthy drug treated cells,
which restricts the morphological feature space learned by the model during training. The
model can only learn the regions corresponding to the uninfected and SARS-CoV-2 in-
fected cell morphology, and it is unaware of the space structure outside of these regions.
Including additional classes into the training dataset would allow the model to learn a
wider range of morphological variations and enable it to differentiate between treatments
that are ineffective from those that are impacting cell morphology through toxicity or any
other mechanisms; thus a better control over the false negative rate would be in place. We
noticed clear cases of drug toxicity with multiple compounds in the dataset, where high
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concentrations clearly disrupted cell morphology. These sample images lack a detectable
signal for the different cell structures and thus we decided to exclude them from the treated
test set. Training the model to identify cellular morphology associated with drug toxicity
would support the identification of the compound and corresponding concentrations with
optimal efficacy and minimal toxicity [65].
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Figure 5.8: DEEMD estimated efficacy scores for identified treatments for different k values.
Similar plots to those in Fig 5.4 for treatments in EM(θ), based on multiple choices of k.
The logistic curves are fitted based on each value for k. The blue curves represents the MIL
model with k = 2 which showed the best classification performance on the validation set.
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Figure 5.9: DEEMD dose-dependent efficacy scores for all identified treatments in EM(θ).
DEEMD dose-dependent efficacy scores in form of violin plots, similar to Fig 5.4. X-axis
shows the Log10(Concentration) of each compound and y-axis reflects the estimated efficacy
score. The violin plot is opaque if ecjti > ζ and the blue curve is a logistic regression model




In this work, we present DEEMD: a pipeline capable of estimating the treatment efficacy of
compounds based on morphological analysis of fluorescent-labelled cells. It includes a deep
learning model trained within a MIL framework to extract morphological features corre-
sponding to the predicted SARS-CoV-2 infection versus no infection in micro-populations,
as well as generating an infection map in a weakly supervised fashion. We compared the per-
formance of the MIL modelM(θ) to the conventionally trained whole-image based model
W(φ). As discussed in Chapter 5, both models are capable of accurately distinguishing be-
tween images from uninfected and SARS-CoV-2 infected sample images. By integrating a
statistical test into the pipeline, DEEMD identifies efficacious compounds that have been
reported to have antiviral effectiveness against SARS-CoV-2 using other methods, support-
ing the performance of the proposed pipeline, whereas the whole-image based model W(φ)
fails to estimate meaningful predictions.
High-throughput screening of antiviral compounds against a virus in cell-based sys-
tems requires the use of commercially available virus-specific antibodies or engineering of
fluorescent-tagged virus particles which are not trivial to develop. Although these molecular
tools are invaluable, the cost and time they take to develop can be a limiting factor in the
initial stages of an outbreak. In that regard, MIL models have an advantage as they may
identify infected cell populations without the need for virus-specific molecular tools. The
RxRx19a dataset was released at the very early stages of the pandemic, hence it lacks a
specific marker for SARS-CoV-2 that could verify if the MIL model M(θ) has correctly
annotated specific patches of cells within an image as infected. Nonetheless, the MIL model
M(θ) is able to accurately distinguish sample images from infected versus non-infected
cells. Validation of the model on images with a marker for SARS-CoV-2 infection would
provide additional confidence to the proposed pipeline and improve the robustness of the
MIL model predictions. This can be done using the viral marker as an attention map within
the training procedure, or as a new term to the model’s loss function.
We only applied DEEMD to the RxRx19a dataset [38] in this work. With the current
configuration, DEEMD is not transferable to other datasets, cell lines, or viruses because it
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was only trained on the HRCE cells with SARS-CoV-2 infection. A version of DEEMD that
is capable of identifying infection-induced morphological changes across multiple viruses
and cell lines can be achieved by leveraging a compiled dataset of multiple cell lines and
viruses. The training procedure would be the same except for the addition of an auxiliary
input that conditions the model based on the cell line and the virus used in the generation
of each sample input image.
DEEMD is designed to be adopted and applied to other datasets and problems with
few adjustments and modifications. With proper assumptions and data preprocessing, this
pipeline can be applied to any fluorescence microscopy datasets, regardless of the stains and
image size, for treatment efficacy estimation.
In the future, we plan to generate and apply DEEMD to more comprehensive datasets
that include drug-treated, uninfected cells along with specific markers of viral infection that
can be used to properly address the shortcomings and limitations of the current version of
DEEMD. Having treated uninfected samples would have a great impact on morphological
profiling and would bring machine learning-based drug repurposing one step closer to being
widely applied to therapeutics.
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